Volume-Based Purchasing Looms Larger In Post-Coronavirus China
Big Price Cuts In New Round
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
You may also be interested in...
Turnover at the German group's pharma unit has been hit harder than forecast by the coronavirus pandemic and hefty price cuts linked to China's drug procurement policy but Bayer remains upbeat.
'Internet hospitals', electronic prescriptions and online physician and patient education are likely to see increasing importance in a post-coronavirus China, says AstraZeneca's emerging markets head.
Clinical studies in hiatus, marketing on hold, demand directionless and supply disrupted. Pharma firms in China say it’s likely the good old days may never come back.